Out-patient parenteral antimicrobial therapy--a viable option for the management of cutaneous leishmaniasis.
Cutaneous infection with Leishmania braziliensis complex requires treatment with parenteral pentavalent antimonials to prevent development of mucocutaneous leishmaniasis. Patients with imported disease are usually managed in hospital because of concerns over drug toxicity. This study describes the clinical features and outcome of infection treated in the UK in an out-patient setting. Thirteen marines (aged 19-35 years) who acquired leishmaniasis in Belize were studied prospectively. Three had at least two lesions (0. 6-3 cm diameter), eight had regional lymphadenopathy and one had localized painless lymphatic thickening. Histology for amastigotes and PCR for Leishmania braziliensis complex was positive in all. Culture was positive in six. Patients received 1.5-2 g (mean 1.7 g) (20 mg/kg) sodium stibogluconate intravenously daily for 20 days. All developed transient musculoskeletal symptoms and asymptomatic hepatitis. Eleven developed biochemical pancreatitis, and one thrombocytopenia. Three developed transient ECG changes and one herpes zoster. There were four device-related infections, two requiring hospitalization (one required surgical drainage of an abscess). All lesions re-epithelialized. A total of 250 bed-days were saved over a 67-day period. These results indicate that in selected patients, out-patient therapy for cutaneous leishmaniasis with parenteral high-dose sodium stibogluconate may be appropriate, provided there is adequate monitoring of therapy.
Seaton
R A
RA
Infection and Immunodeficiency Unit, and Department of Dermatology, Tayside University Hospitals NHS Trust, and Department of Clinical Parasitology, Hospital for Tropical Diseases, London, UK. aseaton66@aol.com
Morrison
J
J
Man
I
I
Watson
J
J
Nathwani
D
D
D000328:Adult; D000553:Ambulatory Care / Q000458:organization & administration*; D000818:Animals; D000967:Antimony Sodium Gluconate / Q000008:administration & dosage*; D000981:Antiprotozoal Agents / Q000008:administration & dosage*; D006801:Humans; D007262:Infusions, Intravenous; D007892:Leishmania braziliensis; D016773:Leishmaniasis, Cutaneous / Q000188:drug therapy*; D008297:Male; D012646:Self Administration; D016896:Treatment Outcome
D000981:Antiprotozoal Agents; D000967:Antimony Sodium Gluconate